Biomarkers in malignant pleural mesothelioma: current status and future directions

被引：18
作者：
Ahmadzada, Tamkin [1 ]
Reid, Glen [1 ,2 ]
Kao, Steven [2 ,3 ]
机构：
[1] Univ Sydney, Sydney Med Sch, Sydney, NSW, Australia
[2] ADRI, Sydney, NSW, Australia
[3] Chris OBrien Lifehouse, Dept Med Oncol, Sydney, NSW, Australia
来源：
JOURNAL OF THORACIC DISEASE | 2018年 / 10卷
关键词：
DETECT ASBESTOS EXPOSURE; OPEN-LABEL; DIAGNOSIS; PROGNOSIS; TRIAL; OSTEOPONTIN; EXPRESSION; FIBULIN-3; HMGB1;
D O I：
10.21037/jtd.2018.04.31
中图分类号：
R56 [呼吸系及胸部疾病];
学科分类号：
摘要：
引用
收藏
页码：S1003 / S1007
页数：5
相关论文
共 25 条
[1]   Clinical safety and activity of pembrolizumab in patients with malignant pleural mesothelioma (KEYNOTE-028): preliminary results from a non-randomised, open-label, phase 1b trial [J].
Alley, Evan W. ;
Lopez, Juanita ;
Santoro, Armando ;
Morosky, Anne ;
Saraf, Sanatan ;
Piperdi, Bilal ;
van Brummelen, Emilie .
LANCET ONCOLOGY, 2017, 18 (05) :623-630
[2]   Progress and challenges in Mesothelioma: From bench to bedside [J].
Blyth, Kevin G. ;
Murphy, Daniel J. .
RESPIRATORY MEDICINE, 2018, 134 :31-41
[3]   Prognostic significance of neutrophil-to-lymphocyte ratio in patients with malignant pleural mesothelioma: a meta-analysis [J].
Chen, Nan ;
Liu, Shuai ;
Huang, Lin ;
Li, Wanling ;
Yang, Wenhao ;
Cong, Tianxin ;
Ding, Lin ;
Qiu, Meng .
ONCOTARGET, 2017, 8 (34) :57460-57469
[4]   Malignant Mesothelioma Biomarkers From Discovery to Use in Clinical Practice for Diagnosis, Monitoring, Screening, and Treatment [J].
Creaney, Jenette ;
Robinson, Bruce W. S. .
CHEST, 2017, 152 (01) :143-149
[5]   Utility of osteopontin and serum mesothelin in malignant pleural mesothelioma diagnosis and prognosis assessment [J].
Grigoriu, Bogdan-Dragos ;
Scherpereel, Arnaud ;
Devos, Patrick ;
Chahine, Bachar ;
Letourneux, Marc ;
Lebailly, Pierre ;
Gregoire, Marc ;
Porte, Henri ;
Copin, Marie-Christine ;
Lassalle, Philippe .
CLINICAL CANCER RESEARCH, 2007, 13 (10) :2928-2935
[6]   Nintedanib Plus Pemetrexed/Cisplatin in Patients With Malignant Pleural Mesothelioma: Phase II Results From the Randomized, Placebo-Controlled LUME-Meso Trial [J].
Grosso, Federica ;
Steele, Nicola ;
Novello, Silvia ;
Nowak, Anna K. ;
Popat, Sanjay ;
Greillier, Laurent ;
John, Thomas ;
Leighl, Natasha B. ;
Reck, Martin ;
Taylor, Paul ;
Planchard, David ;
Sorensen, Jens Benn ;
Socinski, Mark A. ;
von Wangenheim, Ute ;
Loembe, Arsene Bienvenu ;
Barrueco, Jose ;
Morsli, Nassim ;
Scagliotti, Giorgio .
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (31) :3591-+
[7]   Diagnostic accuracy of osteopontin for malignant pleural mesothelioma: A systematic review and meta-analysis [J].
Hu, Zhi-De ;
Liu, Xiao-Fei ;
Liu, Xiao-Cui ;
Ding, Chun-Mei ;
Hu, Cheng-Jin .
CLINICA CHIMICA ACTA, 2014, 433 :44-48
[8]   Tumor Suppressor microRNAs Contribute to the Regulation of PD-L1 Expression in Malignant Pleural Mesothelioma [J].
Kao, Steven C. ;
Cheng, Yuen Yee ;
Williams, Marissa ;
Kirschner, Michaela B. ;
Madore, Jason ;
Lum, Trina ;
Sarun, Kadir H. ;
Linton, Anthony ;
McCaughan, Brian ;
Klebe, Sonja ;
van Zandwijk, Nico ;
Scolyer, Richard A. ;
Boyer, Michael J. ;
Cooper, Wendy A. ;
Reid, Glen .
JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (09) :1421-1433
[9]   The predictive role of serum VEGF in an advanced malignant mesothelioma patient cohort treated with thalidomide alone or combined with cisplatin/gemcitabine [J].
Kao, Steven Chuan-Hao ;
Harvie, Rozelle ;
Paturi, Florian ;
Taylor, Robyn ;
Davey, Ross ;
Abraham, Rick ;
Clarke, Stephen ;
Marx, Gavin ;
Cullen, Martin ;
Kerestes, Zoltan ;
Pavlakis, Nick .
LUNG CANCER, 2012, 75 (02) :248-254
[10]   Fibulin-3 levels in malignant pleural mesothelioma are associated with prognosis but not diagnosis [J].
Kirschner, Michaela B. ;
Pulford, Emily ;
Hoda, Mir Alireza ;
Rozsas, Anita ;
Griggs, Kim ;
Cheng, Yuen Yee ;
Edelman, J. James B. ;
Kao, Steven C. ;
Hyland, Rebecca ;
Dong, Yawen ;
Laszlo, Viktoria ;
Klikovits, Thomas ;
Vallely, Michael P. ;
Grusch, Michael ;
Hegedus, Balazs ;
Dome, Balazs ;
Klepetko, Walter ;
van Zandwijk, Nico ;
Klebe, Sonja ;
Reid, Glen .
BRITISH JOURNAL OF CANCER, 2015, 113 (06) :963-969
123